The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Ii there anyone else who has just held their shares with the same broker since they delisted from AIM?
How do I transfer this holding to ASX to get them holding an actual value again? I was hoping they were always going to re-list on Aim or UK based exchange again. In truth I've been lazy in sorting bits out on this and need to get it done now.
Thanks
for SCLP as a whole job lot. Again we have a market value for similar IP and technology from Affirmeds deal and Sclp have 3 x the potential. Shows what a joke either AIM or NASDAQ are in terms of clinical stage valuations?? As ever GLA and we wait for the tree to bear fruit!!
Worth a read with the connection with Keytruda and CRUK
http://www.dailymail.co.uk/health/article-6103647/Is-Michael-proof-doctors-FINALLY-secret-weapon-beat-cancer.html
If we can p[lease break out of this latest range and get back to 15p+ in the next couple of weeks and then slowly climb towards the Grand Challenge result hopes... it would be magical :-). Really thought after the placing and with news to come we would be nearer 20p currently and aiming for 50p year end...put PR as ever has been less than enthusiastic, as has the market sentiment. Well hold for gold... GLA
Inanaco
So with this understanding and opinion you have, why has it been that SCLP has had to raise capital rather than partner for the SCIB1 trial? Do you think that it is because they themselves believe the outcome will be leading class data and therefore do not wish to partner at a discount before they prove this and then sell for a much higher figure and royalty agreement?
And with the platforms, do you not think they should be using them to partner with numerous pharma as Biontech seem to be in order to speed up these areas of research while also increasing the company mcap and value?
Thank you
Ok.... so can someone with a better science based and overall market understanding help me understand what is so different between Biontech and SCLP? Biontech do seem to have a good pipeline, but have nothing passed P1 trials that I could see on their pipeline chart. With SCIB 1 going into P1/2 trials and the two in house platforms Immunobody and Moditope why have we thus far seemingly struggled for similar partnerships? Or alternatively where do the partnering deals Biontech have secured value what we have to potentially partner?
Thank you
To exit a company with Sclp apparent potential? I really think we need some clear and concise communication from the BOD on all programme updates and potential monetisation of all this great data and IP as it stands now. The SP bleeding how it is just doesn’t make sense and is not in the interest of the shareholders!
Potnak So if this is a successful treatment what market share do you think are we looking at? On a 30% we would be seeing £10m a year royalties with serious potential for uplift???... or are royalties paid from profit only? As well as getting the full £70m from milestone payments it is some serious money for Sars now minor play here! What do you feel is the timeline on this if successful 3-5yrs?
Potnak
Do you think SAR may get the compounds ready for P1 trials and sell out, if so, what sort of figures would a fair deal be? I just think that although keeping trials in house gives better potential/value ultimately, I'm not sure SAR are really set up to progress much further than they are?
Thanks
very thin hear, especially with the lack of positive PR behind the 'seemingly' good scientific progress. The BOD really do need to address this and be true to their previous words regards getting good value for investors. Right now I'd begrudgingly consider a T/O as low as £1p/s, which is ridiculous given the huge potential here, but news just seems to be standing still and hurting the SP....Or we are days/weeks away from a very good licence deal and just dotting the I's etc.....need an update of progress and timelines IMO to see where we are truly at, all a bit cloak and dagger at the minute. GLA
Come on BOD, get your finger out and bang that bleeding drum a bit!! It's not too much to ask for, to look after the SP and Mcap progress, whilst we are supposedly going into a transformational period for the company!! We may in part me here for the good of science and a step in the direction for curing cancer, but at the same time we have backed the company with our money, because we have trusted the science and the Bod to see this through. The science seems to be looking after it's self, but the BOD are not helping with any nervous or faltering investors with the lack of direct PR. Frustrating to see the slide again, was hoping this would be 30-40p by November, but not so sure now.
Morning, you have stood by the idea that Scancell is way undervalued because no one has grasped the full IP potential here and what this will/can lead too. Now I am not saying you're wrong regards the PI and II and therefore the market generally, but you cannot still believe that the big pharma doctors/researchers are missing the same thing here. It isn't like this has developed overnight and I am sure there are some of the big companies looking at Scancell and what they have with great interest. Therefore there must be other reasons why nothing has come via an RNS, especially since the company was ready for sale way back....so there must have been something worth selling then already!! Do you think that a reason there has been no official approaches may be because of the current tie up and challenge work with the other parties, and whatever now happens, they may have a first refusal/right for a licence deal or TO in place? I just don't think the thought line of the big pharmas not grasping SCLP concepts is very likely anymore?
So much for the hope of a progressing SP since raising and patent approval.... getting frustrated now with the lack of push from SCLP on the PR front to go along with the news we've had and the future plans. They do at some point need to be in a position to hold a much larger MCAP value to either list on another exchange or when it comes to negotiating any deals. That doesn't mean I don't believe in the science and potential to shine through at some point, but IMO a steady rise from here is better than sharp changes and the usual trading frenzy they bring when they occur. Anyway WDIK and GLA....it'll all come good one day!!